| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||||
Net loss | ||||||||||||
-19,718 | -22,411 | -34,787 | -32,105 | -36,230 | -27,162 | -57,260 | -36,950 | -7,339 | -28,395 | -23,308 | -38,668 | -41,025 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Depreciation and amortization | ||||||||||||
1,086 | 1,009 | 1,001 | 928 | 879 | 845 | 759 | 797 | 868 | 1,088 | 921 | 848 | 816 |
Stock-based compensation expense | ||||||||||||
2,261 | 2,662 | 2,148 | 3,297 | 1,778 | 2,352 | 2,415 | 3,543 | 2,701 | 2,881 | 2,890 | 6,675 | 2,145 |
Loss on derivative liability | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | -6,548 | -4,587 | -4,276 |
Amortization of debt discount | ||||||||||||
256 | 256 | 257 | 256 | 257 | - | - | - | - | 0 | 309 | 1,856 | 1,184 |
Deferred rent expense | ||||||||||||
- | - | - | - | - | -67 | 7 | 490 | -168 | 1,496 | -216 | -632 | 208 |
Gain on disposal of assets | ||||||||||||
- | - | - | - | - | - | - | 0 | 62 | - | - | - | - |
Loss on disposal of assets and impairment charges | ||||||||||||
-173 | - | - | - | - | - | - | - | - | 0 | 0 | -1 | -79 |
Research and development license fees settled with convertible bond and stock | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 6,250 | 7,000 |
Deferred income taxes | ||||||||||||
48 | 0 | 0 | 0 | 486 | -49 | -21 | 26 | -321 | -219 | 0 | -16 | -92 |
Changes in operating assets and liabilities: | ||||||||||||
Receivables, net | ||||||||||||
34,728 | -479 | 7,604 | -11,011 | 7,624 | 5,880 | 1,933 | -2,707 | -623 | 2,009 | 2,676 | 1,850 | -844 |
Prepaid expenses and other assets | ||||||||||||
-3,748 | -17,950 | -8,224 | 13,399 | 11,911 | 7,676 | 2,031 | 4,753 | -494 | 1,815 | 1,898 | -606 | 1,430 |
Inventories | ||||||||||||
3,101 | 4,180 | 1,212 | 2,048 | -3,596 | 3,556 | 3,428 | 3,232 | 2,010 | 4,926 | 2,375 | 2,425 | 2,595 |
Accounts payable and accrued expenses | ||||||||||||
4,430 | -19,113 | -4,598 | 27,258 | 15,798 | 6,565 | -5,595 | 10,405 | -7,848 | 15,311 | 5,123 | -9,480 | 7,837 |
Net cash used in operating activities | ||||||||||||
-45,545 | -23,340 | -36,347 | -4,802 | -32,971 | -34,072 | -37,286 | -25,303 | -12,726 | -17,868 | -14,841 | -28,050 | -20,753 |
Purchase of property and equipment | ||||||||||||
1,736 | 5,059 | 3,622 | 3,973 | 918 | 820 | 866 | 458 | 1,177 | 1,056 | 942 | 1,888 | 1,554 |
Payments for licenses | ||||||||||||
64 | 0 | 0 | 0 | 4,175 | - | - | - | - | - | - | - | - |
Purchases of short-term investments | ||||||||||||
23,571 | - | - | - | - | 2,654 | 39,515 | 3,834 | 67,256 | 0 | 22,080 | 30,151 | 3,051 |
Sales and maturities of short-term investments | ||||||||||||
14,920 | - | 14,999 | 0 | 57,291 | - | - | - | - | - | - | - | - |
Sale of short-term investments | ||||||||||||
- | - | - | - | - | - | - | - | 11,633 | 38,030 | 2,457 | 3,029 | 8,628 |
Net cash (used in) provided by investing activities | ||||||||||||
-10,451 | 4,911 | -2,176 | -47,434 | 52,198 | 32,162 | -24,572 | 247 | -56,800 | 37,004 | -20,485 | -30,560 | 4,023 |
Cash flows from financing activities: | ||||||||||||
Proceeds from sale of stock | ||||||||||||
- | - | - | - | - | 468 | 50,000 | 0 | 72,666 | - | - | - | - |
Proceeds from issuance of convertible bonds | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 20,000 | 10,000 |
Proceeds from issuance of debt | ||||||||||||
435 | 0 | 2,815 | 2,906 | 743 | - | - | - | - | - | - | - | - |
Costs incurred related to the sale of stock | ||||||||||||
- | - | - | - | - | 400 | 507 | 0 | 4,611 | 0 | 1,124 | 8,414 | 630 |
Proceeds from exercise of stock options | ||||||||||||
344 | 579 | 567 | 559 | 278 | 996 | 1,401 | 296 | 1,263 | 1,070 | 769 | 396 | 43 |
Investment from non-controlling interest | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 49 |
Repayment of finance lease obligations and long-term debt | ||||||||||||
47 | 836 | 29 | 62 | 45 | -7 | 36 | 178 | 337 | 267 | 343 | 292 | 261 |
Net cash provided by financing activities | ||||||||||||
732 | 59,401 | 3,353 | 103,722 | 976 | 671 | 99,265 | 118 | 68,981 | 803 | -698 | 87,590 | 9,201 |
Net (decrease) increase in cash and cash equivalents | ||||||||||||
-55,264 | 40,972 | -35,170 | 51,486 | 20,203 | -1,239 | 37,407 | -24,938 | -545 | 19,939 | -36,024 | 28,980 | -7,529 |
Effect of exchange rate changes on cash and cash equivalents | ||||||||||||
-427 | -203 | -123 | -291 | 1,006 | -75 | -367 | -211 | 478 | 83 | 136 | 136 | 438 |
Supplemental cash flow disclosures | ||||||||||||
Interest paid | ||||||||||||
1,390 | 510 | 1,944 | 1,490 | 981 | - | - | - | 13 | - | - | - | - |
Non-cash investing and financing activities: | ||||||||||||
Accrued purchases of property and equipment | ||||||||||||
1,009 | -623 | -68 | 540 | 634 | -105 | 312 | 29 | 104 | 6 | 70 | -1,000 | 1,080 |
Accrued purchases of licenses | ||||||||||||
500 | - | - | - | - | - | - | - | - | - | - | - | - |
ROU assets derecognized from modification of operating lease obligations | ||||||||||||
-468 | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of equity raise in accounts payable and accrued expenses | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 389 | 735 |
Accrued purchases of pharmaceutical licenses | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 1,550 |
Convertible bond issued in lieu of licensing cash payment | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 7,000 |
ROU assets recognized in exchange for operating lease obligations | ||||||||||||
353 | - | 0 | 0 | 583 | - | - | - | - | - | - | - | - |